DGIdb - PRAVASTATIN Drug Record

PRAVASTATIN chembl:CHEMBL1144 Approved

Alternate Names:

PRAVACHOL
PRAVASTATIN
C10AA03
(+)-(3R,5R)-3,5-DIHYDROXY-7-[(1S,2S,6S,8S,8AR)-6-HYDROXY-2-METHYL-8-{[(S)-2-METHYLBUTYRYL]OXY}-1,2,6,7,8,8A-HEXAHYDRO-1-NAPHTHYL]HEPTANOIC ACID
PRAVACHOL®
PRAVASTATINA
PRAVASTATIN ACID
LIPOSTAT®
PRAVASTATIN SODIUM
PRAVASTATINE
PRAVASTATINUM
chemidplus:81093-37-0
chembl:CHEMBL1144
drugbank:00175
rxcui:42463
pubchem.compound:54687

Drug Info:

Drug Categories	hydroxymethylglutaryl-coa reductase inhibitors
Drug Indications	anticholesterolaemic agent
FDA Approval	approved
Drug Class	Small Molecule
Drug Indications	antihypecholesterolemic agent
Drug Class	anticholesteremic agents
Year of Approval	1991
Drug Categories	agents causing muscle toxicity
Drug Categories	bsep/abcb11 substrates
Drug Categories	drugs causing inadvertant photosensitivity
Drug Categories	hypolipidemic agents indicated for hyperlipidemia
Drug Categories	lipid modifying agents, plain
Drug Categories	oat1/slc22a6 inhibitors
Drug Categories	oat3/slc22a8 inhibitors
Drug Categories	oat3/slc22a8 substrates
Drug Categories	oatp1b3 substrates
Drug Categories	p-glycoprotein substrates
Drug Categories	photosensitizing agents

(4 More Sources)

Publications:

Maitland-van der Zee AH et al., 2008, Interactions between the single nucleotide polymorphisms in the homocysteine pathway (MTHFR 677C>T, MTHFR 1298 A>C, and CBSins) and the efficacy of HMG-CoA reductase inhibitors in preventing cardiovascular disease in high-risk patients of hypertension: the GenHAT study., Pharmacogenet Genomics
Li J et al., 2009, Effect of R219K polymorphism of the ABCA1 gene on the lipid-lowering effect of pravastatin in Chinese patients with coronary heart disease., Clin Exp Pharmacol Physiol
Voora D et al., 2008, Pharmacogenetic predictors of statin-mediated low-density lipoprotein cholesterol reduction and dose response., Circ Cardiovasc Genet
Medina MW et al., 2012, RHOA is a modulator of the cholesterol-lowering effects of statin., PLoS Genet
Mazaleuskaya LL et al., 2015, PharmGKB summary: ibuprofen pathways., Pharmacogenet Genomics
Zheng et al., 2005, [Effects of interaction between vascular endothelial cells and monocytes on expression of matrix metalloproteinase-2 and of tissue inhibitor of metalloproteinases 2 and regulation of pravastatin]., Zhonghua Bing Li Xue Za Zhi
Boekholdt SM et al., 2003, Variants of toll-like receptor 4 modify the efficacy of statin therapy and the risk of cardiovascular events., Circulation
Niemi M et al., 2006, Association of genetic polymorphism in ABCC2 with hepatic multidrug resistance-associated protein 2 expression and pravastatin pharmacokinetics., Pharmacogenet Genomics
Mega JL et al., 2009, Identification of genetic variants associated with response to statin therapy., Arterioscler Thromb Vasc Biol
Chen et al., 2005, Differential interaction of 3-hydroxy-3-methylglutaryl-coa reductase inhibitors with ABCB1, ABCC2, and OATP1B1., Drug Metab. Dispos.
Thompson JF et al., 2005, An association study of 43 SNPs in 16 candidate genes with atorvastatin response., Pharmacogenomics J
Lahoz C et al., 2005, The -514C/T polymorphism of the hepatic lipase gene significantly modulates the HDL-cholesterol response to statin treatment., Atherosclerosis
Shiffman D et al., 2010, Effect of pravastatin therapy on coronary events in carriers of the KIF6 719Arg allele from the cholesterol and recurrent events trial., Am J Cardiol
Iakoubova OA et al., 2008, Association of the Trp719Arg polymorphism in kinesin-like protein 6 with myocardial infarction and coronary heart disease in 2 prospective trials: the CARE and WOSCOPS trials., J Am Coll Cardiol
Iakoubova OA et al., 2008, Polymorphism in KIF6 gene and benefit from statins after acute coronary syndromes: results from the PROVE IT-TIMI 22 study., J Am Coll Cardiol
Iakoubova OA et al., 2010, KIF6 Trp719Arg polymorphism and the effect of statin therapy in elderly patients: results from the PROSPER study., Eur J Cardiovasc Prev Rehabil
Schmidt et al., Severe rhabdomyolysis and acute renal failure secondary to concomitant use of simvastatin, amiodarone, and atazanavir., J Am Board Fam Med
Sai K et al., 2016, A possible role for HLA-DRB1*04:06 in statin-related myopathy in Japanese patients., Drug Metab Pharmacokinet
Bessler et al., 2005, In vitro effect of statins on cytokine production and mitogen response of human peripheral blood mononuclear cells., Clin. Immunol.
Parhofer et al., 1993, Effect of pravastatin on metabolic parameters of apolipoprotein B in patients with mixed hyperlipoproteinemia., Clin Investig
Polisecki E et al., 2010, Genetic variation at the NPC1L1 gene locus, plasma lipoproteins, and heart disease risk in the elderly., J Lipid Res
Singer JB et al., 2007, Genetic analysis of fluvastatin response and dyslipidemia in renal transplant recipients., J Lipid Res
Ye YC et al., 2015, Use of atorvastatin in lipid disorders and cardiovascular disease in Chinese patients., Chin Med J (Engl)
Donnelly LA et al., 2008, A paucimorphic variant in the HMG-CoA reductase gene is associated with lipid-lowering response to statin treatment in diabetes: a GoDARTS study., Pharmacogenet Genomics
Krauss RM et al., 2008, Variation in the 3-hydroxyl-3-methylglutaryl coenzyme a reductase gene is associated with racial differences in low-density lipoprotein cholesterol response to simvastatin treatment., Circulation
Ray SK et al., 2000, Atorvastatin: in the management of hyperlipidaemia., J Postgrad Med
Polisecki E et al., 2008, Genetic variation at the LDL receptor and HMG-CoA reductase gene loci, lipid levels, statin response, and cardiovascular disease incidence in PROSPER., Atherosclerosis
Chasman DI et al., 2004, Pharmacogenetic study of statin therapy and cholesterol reduction., JAMA
Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
Regieli JJ et al., 2008, CETP genotype predicts increased mortality in statin-treated men with proven cardiovascular disease: an adverse pharmacogenetic interaction., Eur Heart J
Carlquist JF et al., 2003, The cholesteryl ester transfer protein Taq1B gene polymorphism predicts clinical benefit of statin therapy in patients with significant coronary artery disease., Am Heart J
Knoblauch H et al., 2004, Haplotypes and SNPs in 13 lipid-relevant genes explain most of the genetic variance in high-density lipoprotein and low-density lipoprotein cholesterol., Hum Mol Genet
Kuivenhoven JA et al., 1998, The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis. The Regression Growth Evaluation Statin Study Group., N Engl J Med
Mohrschladt MF et al., 2005, TaqIB polymorphism in CETP gene: the influence on incidence of cardiovascular disease in statin-treated patients with familial hypercholesterolemia., Eur J Hum Genet
de Maat MP et al., 1999, Effect of the stromelysin-1 promoter on efficacy of pravastatin in coronary atherosclerosis and restenosis., Am J Cardiol
Sabatine MS et al., 2008, Association between ADAMTS1 matrix metalloproteinase gene variation, coronary heart disease, and benefit of statin therapy., Arterioscler Thromb Vasc Biol
Demyanets et al., 2006, Hydroxymethylglutaryl-coenzyme A reductase inhibitors induce apoptosis in human cardiac myocytes in vitro., Biochem. Pharmacol.
Igel et al., 2006, Impact of the SLCO1B1 polymorphism on the pharmacokinetics and lipid-lowering efficacy of multiple-dose pravastatin., Clin. Pharmacol. Ther.
Ruaño G et al., 2007, Physiogenomic association of statin-related myalgia to serotonin receptors., Muscle Nerve
Keskitalo JE et al., 2009, Different effects of the ABCG2 c.421C>A SNP on the pharmacokinetics of fluvastatin, pravastatin and simvastatin., Pharmacogenomics
Ho et al., 2007, Effect of drug transporter genotypes on pravastatin disposition in European- and African-American participants., Pharmacogenet. Genomics
Ledmyr H et al., 2004, The microsomal triglyceride transfer protein gene-493T variant lowers cholesterol but increases the risk of coronary heart disease., Circulation
Zuccaro P et al., 2007, Tolerability of statins is not linked to CYP450 polymorphisms, but reduced CYP2D6 metabolism improves cholesteraemic response to simvastatin and fluvastatin., Pharmacol Res
Lehtimäki T et al., 2003, Interleukin-1B genotype modulates the improvement of coronary artery reactivity by lipid-lowering therapy with pravastatin: a placebo-controlled positron emission tomography study in young healthy men., Pharmacogenetics
Verma et al., 2004, Novel cardioprotective effects of pravastatin in human ventricular cardiomyocytes subjected to hypoxia and reoxygenation: beneficial effects of statins independent of endothelial cells., J. Surg. Res.
Bray PF et al., 2001, The platelet Pl(A2) and angiotensin-converting enzyme (ACE) D allele polymorphisms and the risk of recurrent events after acute myocardial infarction., Am J Cardiol
Marian AJ et al., 2000, Interactions between angiotensin-I converting enzyme insertion/deletion polymorphism and response of plasma lipids and coronary atherosclerosis to treatment with fluvastatin: the lipoprotein and coronary atherosclerosis study., J Am Coll Cardiol
Mulder HJ et al., 2003, DD ACE gene polymorphism is associated with increased coronary artery endothelial dysfunction: the PREFACE trial., Heart
Lin et al., 2008, Statins increase p21 through inhibition of histone deacetylase activity and release of promoter-associated HDAC1/2., Cancer Res.

PRAVASTATIN ADAMTS1

Interaction Score: 3.16

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
18174457

Sources:
PharmGKB
PRAVASTATIN KIF6

Interaction Score: 1.97

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
20403483 18222353 18222355 20215968

Sources:
PharmGKB
PRAVASTATIN NPC1L1

Interaction Score: 1.58

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
19752398

Sources:
PharmGKB
PRAVASTATIN HMGCR

Interaction Score: 0.85

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name CRES pravastatin

Novel drug target Established target

Trial Name pravastatin and fenofibrate,PravaFen

PMIDs:
17563401 25591572 18815589 18332269 11298482 16103896 18261733 15199031 11752352

Sources:
TEND PharmGKB TdgClinicalTrial TTD DrugBank GuideToPharmacology
PRAVASTATIN CETP

Interaction Score: 0.79

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
18957472 14660992 15044381 9420339 15856070

Sources:
PharmGKB
PRAVASTATIN LIPC

Interaction Score: 0.68

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16103896 16115483

Sources:
PharmGKB
PRAVASTATIN RHOA

Interaction Score: 0.63

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
23166513

Sources:
PharmGKB
PRAVASTATIN ABCA1

Interaction Score: 0.59

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
19673941 20031551

Sources:
PharmGKB
PRAVASTATIN MTTP

Interaction Score: 0.35

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
15136504

Sources:
PharmGKB
PRAVASTATIN APOE

Interaction Score: 0.24

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
19667110 17289397

Sources:
PharmGKB
PRAVASTATIN HTR3B

Interaction Score: 0.21

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
17600820

Sources:
PharmGKB
PRAVASTATIN APOB

Interaction Score: 0.17

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
8312689

Sources:
NCI
PRAVASTATIN TLR4

Interaction Score: 0.17

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
12742999

Sources:
PharmGKB
PRAVASTATIN SLC22A6

Interaction Score: 0.16

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
PRAVASTATIN ABCB11

Interaction Score: 0.16

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
PRAVASTATIN LPL

Interaction Score: 0.15

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16103896

Sources:
PharmGKB
PRAVASTATIN MTHFR

Interaction Score: 0.12

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
18622257

Sources:
PharmGKB
PRAVASTATIN MMP3

Interaction Score: 0.12

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
10190398

Sources:
PharmGKB
PRAVASTATIN SLCO1B3

Interaction Score: 0.12

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
25502615

Sources:
PharmGKB
PRAVASTATIN ACE

Interaction Score: 0.11

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
11545752 16103896 10636265 12695469

Sources:
PharmGKB
PRAVASTATIN HLA-DRB1

Interaction Score: 0.1

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
27839692

Sources:
PharmGKB
PRAVASTATIN MMP2

Interaction Score: 0.1

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
15842807

Sources:
NCI
PRAVASTATIN ABCG2

Interaction Score: 0.1

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
19842935 17622941

Sources:
NCI PharmGKB
PRAVASTATIN SLC22A8

Interaction Score: 0.1

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
PRAVASTATIN SLCO1B1

Interaction Score: 0.09

Interaction Types & Directionality:

n/a

Interaction Info:

Specific Action of the Ligand Binding

Endogenous Drug? False

Direct Interaction? False

PMIDs:
16678544

Sources:
NCI GuideToPharmacology
PRAVASTATIN IL2

Interaction Score: 0.08

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16051523

Sources:
NCI
PRAVASTATIN LDLR

Interaction Score: 0.08

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
PRAVASTATIN IL1B

Interaction Score: 0.07

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
14515062

Sources:
PharmGKB
PRAVASTATIN BAX

Interaction Score: 0.07

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16540096

Sources:
NCI
PRAVASTATIN SLCO2B1

Interaction Score: 0.07

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
PRAVASTATIN HDAC2

Interaction Score: 0.06

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

PMIDs:
18381445

Sources:
DrugBank
PRAVASTATIN ABCC2

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
17047488

Sources:
PharmGKB
PRAVASTATIN NOS1

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
15126084

Sources:
NCI
PRAVASTATIN HTR7

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
17600820

Sources:
PharmGKB
PRAVASTATIN ABCB1

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
19667110 15616150

Sources:
NCI PharmGKB
PRAVASTATIN CYP3A4

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
17615423

Sources:
NCI

DrugBank: DB00175

Version: 5.1.7

Alternate Names:

PRAVASTATIN DrugBank Drug Name

81093-37-0 CAS Number

Ach-pravastatin Drug Brand

Drug Info:

Drug Type small molecule

Drug Groups approved

Drug Categories agents causing muscle toxicity

Publications:

Lin et al., 2008, Statins increase p21 through inhibition of histone deacetylase activity and release of promoter-associated HDAC1/2., Cancer Res.

Ye YC et al., 2015, Use of atorvastatin in lipid disorders and cardiovascular disease in Chinese patients., Chin Med J (Engl)

Ray SK et al., 2000, Atorvastatin: in the management of hyperlipidaemia., J Postgrad Med

TEND: PRAVASTATIN
- Version: 01-August-2011
Alternate Names:

PRAVASTATIN Primary Drug Name

Drug Info:

Year of Approval 1991

Drug Class anticholesteremic agents

Publications:
TdgClinicalTrial: PRAVASTATIN
- Version: January-2014
Alternate Names:

Drug Info:

Drug Indications antihypecholesterolemic agent

Drug Class Small Molecule

FDA Approval approved

Publications:

NCI: PRAVASTATIN

Version: 14-September-2017

Alternate Names:

C29375 NCI drug code

Drug Info:

Publications:

Igel et al., 2006, Impact of the SLCO1B1 polymorphism on the pharmacokinetics and lipid-lowering efficacy of multiple-dose pravastatin., Clin. Pharmacol. Ther.

Verma et al., 2004, Novel cardioprotective effects of pravastatin in human ventricular cardiomyocytes subjected to hypoxia and reoxygenation: beneficial effects of statins independent of endothelial cells., J. Surg. Res.

Bessler et al., 2005, In vitro effect of statins on cytokine production and mitogen response of human peripheral blood mononuclear cells., Clin. Immunol.

PharmGKB: pravastatin

Version: 18-August-2020

Alternate Names:

Drug Info:

Publications:

Maitland-van der Zee AH et al., 2008, Interactions between the single nucleotide polymorphisms in the homocysteine pathway (MTHFR 677C>T, MTHFR 1298 A>C, and CBSins) and the efficacy of HMG-CoA reductase inhibitors in preventing cardiovascular disease in high-risk patients of hypertension: the GenHAT study., Pharmacogenet Genomics

Shiffman D et al., 2010, Effect of pravastatin therapy on coronary events in carriers of the KIF6 719Arg allele from the cholesterol and recurrent events trial., Am J Cardiol

Iakoubova OA et al., 2008, Association of the Trp719Arg polymorphism in kinesin-like protein 6 with myocardial infarction and coronary heart disease in 2 prospective trials: the CARE and WOSCOPS trials., J Am Coll Cardiol

GuideToPharmacology: 135650848
- Version: 29-September-2020
Alternate Names:

PRAVASTATIN GuideToPharmacology Ligand Name

Drug Info:

Publications:
TTD: Pravastatin
- Version: 2020.06.01
Alternate Names:

D02RQU TTD Drug ID

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL1144
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:

Trial Name	CRES pravastatin
Novel drug target	Established target
Trial Name	pravastatin and fenofibrate,PravaFen

Specific Action of the Ligand	Binding
Endogenous Drug?	False
Direct Interaction?	False

PRAVASTATIN	DrugBank Drug Name
81093-37-0	CAS Number
Ach-pravastatin	Drug Brand

Drug Type	small molecule
Drug Groups	approved
Drug Categories	agents causing muscle toxicity

PRAVASTATIN Drug Record

PRAVASTATIN chembl:CHEMBL1144 Approved

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 18174457

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 20403483 18222353 18222355 20215968

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 19752398

Sources: PharmGKB

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Trial Name CRES pravastatin Novel drug target Established target Trial Name pravastatin and fenofibrate,PravaFen

PMIDs: 17563401 25591572 18815589 18332269 11298482 16103896 18261733 15199031 11752352

Sources: TEND PharmGKB TdgClinicalTrial TTD DrugBank GuideToPharmacology

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 18957472 14660992 15044381 9420339 15856070

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 16103896 16115483

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 23166513

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 19673941 20031551

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 15136504

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 19667110 17289397

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 17600820

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 8312689

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 12742999

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 16103896

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 18622257

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 10190398

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 25502615

Interaction Types & Directionality:

n/a

PMIDs:
18174457

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
20403483 18222353 18222355 20215968

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
19752398

Sources:
PharmGKB

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name CRES pravastatin

Novel drug target Established target

Trial Name pravastatin and fenofibrate,PravaFen

PMIDs:
17563401 25591572 18815589 18332269 11298482 16103896 18261733 15199031 11752352

Sources:
TEND PharmGKB TdgClinicalTrial TTD DrugBank GuideToPharmacology

Interaction Types & Directionality:

n/a

PMIDs:
18957472 14660992 15044381 9420339 15856070

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
16103896 16115483

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
23166513

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
19673941 20031551

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
15136504

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
19667110 17289397

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
17600820

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
8312689

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
12742999

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
16103896

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
18622257

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
10190398

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
25502615

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
11545752 16103896 10636265 12695469

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
27839692

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
15842807

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
19842935 17622941

Sources:
NCI PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

Interaction Info:

Specific Action of the Ligand Binding

Endogenous Drug? False

Direct Interaction? False

PMIDs:
16678544

Sources:
NCI GuideToPharmacology

Interaction Types & Directionality:

n/a

PMIDs:
16051523

Sources:
NCI